A recent study suggests that altering the guidelines for prescribing statins could potentially save thousands of lives. Researchers found that combining a statin with another drug called ezetimibe, rather than using statins alone, could be a more effective approach in lowering “bad” cholesterol levels in patients with blocked arteries.

The study, which analyzed data from 14 previous studies involving over 100,000 high-risk patients, revealed that the combination therapy of ezetimibe and a high-dose statin led to a significant 19% reduction in overall mortality risk. Additionally, there was a 16% decrease in cardiovascular-related deaths and notable reductions in major adverse cardiovascular events and strokes by 18% and 17%, respectively, compared to using high-dose statins alone.

By combining ezetimibe with statins, LDL-C levels were further reduced by 13mg/dL, aiding in achieving the ideal target of less than 70mg/dL. The study’s lead author, Professor Maciej Banach, emphasized the efficacy and safety of this combined therapy, highlighting its potential to significantly lower the risk of adverse cardiovascular events and deaths.

The research findings support the immediate consideration of combined cholesterol-lowering therapy for high-risk patients, even before experiencing a heart attack or stroke. Professor Peter Toth, a co-author of the study, emphasized the importance of this approach in achieving optimal LDL-C goals and reducing cardiovascular health issues and mortality rates.

The study estimates that implementing combination therapy in treatment guidelines could prevent over 330,000 deaths annually among heart attack survivors, with nearly 50,000 lives saved in the United States alone. The recommendation is to make combination therapy the standard treatment for high-risk patients and integrate it into future healthcare guidelines.

Statins have a long history of safe use in lowering LDL-C levels by inhibiting its production in the liver, while ezetimibe complements this action by reducing cholesterol absorption in the intestines. For patients who do not respond adequately to statins alone, the addition of ezetimibe has shown to be beneficial.

In conclusion, the study underscores the significance of early and comprehensive cholesterol-lowering therapy for high-risk patients to enhance long-term cardiovascular health and reduce the risk of complications and fatalities.